310 related articles for article (PubMed ID: 32022277)
1. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.
Natarajan Y; Kramer JR; Yu X; Li L; Thrift AP; El-Serag HB; Kanwal F
Hepatology; 2020 Oct; 72(4):1242-1252. PubMed ID: 32022277
[TBL] [Abstract][Full Text] [Related]
2. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY
Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327
[TBL] [Abstract][Full Text] [Related]
3. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease.
Navarroza AMC; Wong SN
Indian J Gastroenterol; 2021 Aug; 40(4):380-388. PubMed ID: 34213749
[TBL] [Abstract][Full Text] [Related]
5. Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to Hepatocellular Carcinoma Development Without Cirrhosis.
Phan J; Ng V; Sheinbaum A; French S; Choi G; El Kabany M; Durazo F; Saab S; Tong M; Busuttil R; Han SH
J Clin Gastroenterol; 2019 Apr; 53(4):309-313. PubMed ID: 29912756
[TBL] [Abstract][Full Text] [Related]
6. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
7. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
Simon TG; Roelstraete B; Sharma R; Khalili H; Hagström H; Ludvigsson JF
Hepatology; 2021 Nov; 74(5):2410-2423. PubMed ID: 33811766
[TBL] [Abstract][Full Text] [Related]
8. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.
Huang DQ; Tran S; Barnett S; Zou B; Yeo YH; Cheung R; Nguyen MH
Hepatol Int; 2024 Apr; 18(2):540-549. PubMed ID: 38079023
[TBL] [Abstract][Full Text] [Related]
9. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW
Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781
[TBL] [Abstract][Full Text] [Related]
10. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Li B; Cheung KS; Yuen MF; Seto WK
Hepatol Int; 2021 Aug; 15(4):901-911. PubMed ID: 34152534
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
[TBL] [Abstract][Full Text] [Related]
12. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.
Behari J; Gougol A; Wang R; Luu HN; Paragomi P; Yu YC; Molinari M; Chopra K; Malik SM; Geller D; Yuan JM
Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37395730
[TBL] [Abstract][Full Text] [Related]
13. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
14. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Li L; Dai J; Natarajan Y; Yu X; Asch SM; El-Serag HB
Hepatology; 2020 Mar; 71(3):808-819. PubMed ID: 31675427
[TBL] [Abstract][Full Text] [Related]
15. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013.
Beste LA; Leipertz SL; Green PK; Dominitz JA; Ross D; Ioannou GN
Gastroenterology; 2015 Nov; 149(6):1471-1482.e5; quiz e17-8. PubMed ID: 26255044
[TBL] [Abstract][Full Text] [Related]
16. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
Kogiso T; Sagawa T; Kodama K; Taniai M; Hashimoto E; Tokushige K
J Gastroenterol Hepatol; 2020 Sep; 35(9):1579-1589. PubMed ID: 31975453
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study.
Pinyopornpanish K; Khoudari G; Saleh MA; Angkurawaranon C; Pinyopornpanish K; Mansoor E; Dasarathy S; McCullough A
BMC Gastroenterol; 2021 Oct; 21(1):394. PubMed ID: 34674650
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
20. Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study.
Grecian SM; McLachlan S; Fallowfield JA; Kearns PKA; Hayes PC; Guha NI; Morling JR; Glancy S; Williamson RM; Reynolds RM; Frier BM; Zammitt NN; Price JF; Strachan MWJ
Liver Int; 2020 Sep; 40(9):2252-2262. PubMed ID: 32638496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
